Study to Evaluate the Effect of Single Doses of LX4211 and Canagliflozin on Intestinal Glucose Absorption in Healthy Adult Subjects

Part of paid clinical trials in Chula Vista, California.

Sponsor
Lexicon Pharmaceuticals
Study ID
NCT01916863
Phase
PHASE1
Status
Completed

Conditions

  • Healthy Subjects

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

Study Details

The purpose of this study is to assess the effect of LX4211 and the comparator drug canagliflozin on intestinal glucose absorption and metabolism after a single dose in healthy subjects in comparison to placebo.

Key Dates

Start date
Aug 31, 2013
Status verified
Oct 2013
Primary completion
Oct 31, 2013

Study Design

Enrollment
25 participants (actual)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: LX4211
    400 mg of LX4211
  • Active Comparator: Canagliflozin
    300 mg canagliflozin
  • Placebo Comparator: Placebo
    LX4211 placebo

Primary Outcome Measure

Change from baseline in rate of glucose appearance after meal (RaO) [ Time Frame: Days 1, 8, 15 ]

Locations (1)

FacilityCityStateZIPSite coordinators
Lexicon Investigational SiteChula VistaCalifornia91911-

Find similar trials in Chula Vista, CA

By research site
Lexicon Investigational Site· Chula Vista, CA

Related Studies